CJC-1295 Ipamorelin Dosage: What the Research Actually Administered

The short version

This page reports CJC-1295 Ipamorelin dosage the way the studies recorded it — which species got how much, by which route — and nothing more. It is not a protocol and it is not advice. Two facts shape everything here. First, the two halves run on different clocks: CJC-1295 with its DAC handle lasts days in humans, while ipamorelin lasts a couple of hours at most. Second, the human numbers come from CJC-1295's early Phase 1 pharmacokinetic studies, while almost all of ipamorelin's dosing data comes from rats — and there's no published human study of the pre-mixed combination at all. So you'll see real measured doses below, always tied to the animal or early-human study they came from, never a recommendation to use any of them.

Cjc 1295 ipamorelin dosage: the research record

CJC-1295 (with DAC), human PK studies. Ascending single and multiple subcutaneous doses of 30 or 60 micrograms per kilogram were administered to healthy adults (ages 21 to 61) to characterize the multi-day GH and IGF-1 response ^[1]. Phase 1 work explored the 30 to 90 micrograms-per-kilogram range. In GHRH-knockout mouse studies, a 2-micrograms-per-day dose was used.

CJC-1295 no-DAC (Mod GRF 1-29). This short-acting form has no formal standalone human PK study; research protocols model it as a brief pulsatile GHRH signal.

Ipamorelin (rodent). Bone-formation work used 100 micrograms per kilogram three times daily ^[9]; bone-mineral-content work used 0.5 milligrams per kilogram per day for 12 weeks ^[10]; GI-motility studies for the ghrelin-agonist class spanned roughly 0.01 to 1 milligram per kilogram intravenously ^[13]. In rodent models, the GH response plateaued near 1 microgram per kilogram. No validated human PK for ipamorelin has been published.

Every figure above is reported as "studied at X in [species] by [route]" — not a human dose.

Half-life: the mismatched clocks

CJC-1295 with DAC has a human half-life on the order of 6 to 8 days — the albumin-bound peptide stays detectable in rat plasma beyond 72 hours ^[5], and the human GH/IGF-1 elevation runs for days ^[1]. CJC-1295 without DAC (Mod GRF 1-29) is on the order of minutes to roughly 30 minutes, like native GRF(1-29), because DPP-IV cleaves it quickly. Ipamorelin clears under about 2 hours in rodent plasma, with a peak GH response near 40 minutes post-dose; no validated human half-life is published. This mismatch — a multi-day GHRH agent paired with a short-acting GHRP — is exactly why the net GH exposure of any given combination protocol is uncharacterized.

Routes studied and handling context

Routes recorded in the literature are subcutaneous and intravenous, with continuous subcutaneous infusion (osmotic minipump) and intranasal delivery appearing in rodent PK work. On handling: lyophilized (freeze-dried) peptide is stable frozen for extended periods. After reconstitution with bacteriostatic water (sterile water with 0.9% benzyl alcohol as a preservative), aqueous peptide solutions are kept refrigerated at 2 to 8 degrees Celsius and degrade over weeks via asparagine deamidation — and degradation products can be markedly less potent. Agitation and repeated freeze-thaw are avoided. GHRH analogues undergo DPP-IV cleavage in plasma; CJC-1295's substitutions and DAC were engineered to resist it. This is standard laboratory-handling context, not a preparation instruction.

What the human clinical record does and doesn't contain

CJC-1295 (DAC) reached Phase 2 before development was discontinued; a Phase 2 program ended after an adverse event in one subject reported as unrelated to the established mechanism. Phase 1 data in healthy adults characterized its PK and dose-response ^[1]. Ipamorelin was investigated — including a postoperative-ileus program in the ghrelin-agonist class ^[13] — but was not advanced to approval. There is no peer-reviewed human pharmacology study of the pre-mixed CJC-1295 Ipamorelin combination itself. Any dosing figure attached to the "blend" therefore comes from single-component studies, not from a trial of the combination — which is why this page reports doses only as what was administered in specific studies, and stops there.